Exhibit 107
Calculation of Filing Fee Tables
FORM S-4
(Form Type)
PHOENIX BIOTECH ACQUISITION CORP.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
Security Type | Security Class Title | Fee Calculation or Carry Forward Rule | Amount Registered(1)(2) | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | Carry Forward Form Type | Carry Forward File Number | Carry Forward Initial effective date | Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward | ||||||||||||||||||||||
Newly Registered Securities | |||||||||||||||||||||||||||||||||
Fees to Be Paid | Equity | Class A Common Stock | 457(f) (2) | 10,493,945 | NA | $ | 349.80 | (3) | 0.0001102 | $ | 0.04 | ||||||||||||||||||||||
Equity | Shares of Class A Common Stock underlying Warrants | 457(f) (2) | 324,999 | NA | $ | 10.83 | (3) | 0.0001102 | $ | 0.01 | |||||||||||||||||||||||
Carry Forward Securities | |||||||||||||||||||||||||||||||||
Carry Forward Securities | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||
Total Offering Amounts | 10,818,944 | $ | 360.63 | (3) | $ | 0.05 | — | ||||||||||||||||||||||||||
Total Fees Previously Paid | — | ||||||||||||||||||||||||||||||||
Total Fee Offsets | — | ||||||||||||||||||||||||||||||||
Net Fee Due | $ | 0.05 | — |
(1) | Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. |
(2) | The number of shares of Class A common stock of Phoenix Biotech Acquisition Corp., par value $0.0001 per share (the “Class A Common Stock”) being registered represents the number of shares of Class A Common Stock to be issued in connection with the proposed merger described herein. |
(3) | Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(f)(2) of the Securities Act. CERo Therapeutics, Inc. is a private company, no market exists for its securities, and it has an accumulated deficit. |